Cleerly has raised $373.0M in total across 3 funding rounds.
Cleerly's investors include Esplanade HealthTech Ventures, Founders Fund, Insight Partners, Northzone, Picus Capital, Presight Capital, Social Capital, Vensana Capital, Pau Gasol, Canaan Partners, Index Ventures, Morgenthaler Ventures.
Cleerly is a digital healthcare company developing an AI-driven platform that analyzes coronary computed tomography angiography (CCTA) images to quantify and assess coronary artery disease (CAD), delivering clinically actionable insights for personalized heart disease treatment and prevention.[1][2][3] It serves clinicians, cardiologists, and healthcare providers by solving the problem of imprecise CAD diagnosis through precise plaque volume, composition, stenosis severity, and ischemia evaluation, potentially reducing unnecessary tests and enabling earlier intervention.[1][3] Cleerly's growth momentum includes FDA-cleared technology, major clinical trials like CREDENCE and PACIFIC demonstrating superior accuracy over alternatives, recent $106 million funding led by Insight Partners, expanding payer coverage to 61 million Americans, and late-breaking presentations at conferences like RSNA 2024, TCT 2025, and CVCT 2025.[1][4][5]
Cleerly emerged as a mission-driven company focused on transforming heart disease care by shifting from symptom-based to proactive, AI-powered analysis of atherosclerosis.[1][2] While specific founders are not detailed in available sources, the company has rapidly advanced from developing its core CCTA analysis platform to achieving FDA clearance and clinical validation through multicenter trials like CREDENCE, which showed Cleerly ISCHEMIA outperforming FFRCT and stress testing against invasive FFR gold standards.[1] Pivotal early traction came from post-hoc PACIFIC study analyses confirming its prognostic value for major adverse cardiac events (MACE), alongside securing $106 million in funding to scale its solutions.[1][4][5]
Cleerly rides the wave of AI in precision medicine and cardiac imaging, addressing CAD—the leading global cause of death—by enabling earlier, non-invasive detection amid rising demand for personalized care.[1][2] Timing aligns with advancing CCTA adoption, post-pandemic focus on preventive cardiology, and AI regulatory progress (FDA clearance), amplified by payer expansions improving access.[4] Market forces like aging populations, trial-validated AI superiority, and registries like CONFIRM2 position it to influence standards, reducing heart attacks via plaque-focused risk stratification over stenosis alone.[1][4][5]
Cleerly is poised to redefine CAD management as payer coverage grows and trials like CONFIRM2 solidify its prognostic edge, potentially becoming the new care standard.[4][5] Trends in AI-quantitative imaging, high-burden plaque thresholds, and multimodal data integration will shape its path, evolving influence through broader clinician adoption and outcomes data. This builds on its core mission: act early with AI to eliminate preventable heart attacks.[1]
Cleerly has raised $373.0M across 3 funding rounds. Most recently, it raised $110.0M Series C in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $110.0M Series C | Esplanade HealthTech Ventures, Founders Fund, Insight Partners, Northzone, Picus Capital, Presight Capital, Social Capital, Vensana Capital, Pau Gasol | |
| Jul 1, 2022 | $220.0M Series C | Canaan Partners, Founders Fund, Index Ventures, Morgenthaler Ventures, Presight Capital, Vensana Capital, Avid Larizadeh, Mato Peric | |
| Jun 1, 2021 | $43.0M Series B | Aglae Ventures, AirAngels, Breakthrough Energy Ventures, Canaan Partners, Esplanade HealthTech Ventures, FJ Labs, Founders Fund, Insight Partners, Lowercarbon Capital, Morgenthaler Ventures, Otherwise Fund, Presight Capital, Serena Ventures, Seven Seven Six, Sherpalo Ventures, Social Capital, Sweet Capital, Unruly Capital, Vensana Capital, World Fund, Azeem Azhar, Claire Hughes Johnson, James Beshara, Manu Ginobilli, Marcos Galperin, Sahil Lavingia, Scott Belsky, Seth Goldman, Tobias Lutke |
